

1 **Using sero-epidemiology to monitor disparities in vaccination and infection with**
2 **SARS-CoV-2**

3
4 Isobel Routledge¹, Saki Takahashi¹, Adrienne Epstein¹, Jill Hakim¹, Owen Janson¹,
5 Keirstinne Turcios¹, Jo Vinden^{1,2}, John Tomas Risos³, Margaret Rose Baniqued³, Lori
6 Pham³, Clara Di Germanio⁴, Michael Busch^{3,4}, Margot Kushel⁵, Bryan Greenhouse¹, Isabel
7 Rodríguez-Barraquer¹

8
9 ¹Department of Medicine, University of California San Francisco, San Francisco, California,
10 USA

11 ²Infectious Disease and Immunity Graduate Group, University of California Berkeley,
12 Berkeley, California, USA

13 ³Department of Laboratory Medicine, University of California San Francisco, San Francisco,
14 California, USA

15 ⁴Vitalant Research Institute, San Francisco, California, USA

16 ⁵Center for Vulnerable Populations, Zuckerberg San Francisco General Hospital and
17 Trauma Center, University of California San Francisco, San Francisco, California, USA

18
19 **Abstract**

20 *Background:* As COVID-19 vaccines continue to be rolled-out, the “double burden” of health
21 disparities in both exposure to infection and vaccination coverage intersect to determine the
22 current and future patterns of infection, immunity, and mortality. Serology provides a unique
23 opportunity to measure biomarkers of infection and vaccination simultaneously, and to relate
24 these metrics to demographic and geographic factors.

25
26 *Methods:* Leveraging algorithmically selected residual serum samples from two hospital
27 networks in San Francisco, we sampled 1014 individuals during February 2021, capturing
28 transmission during the first 11 months of the epidemic and the early roll out of vaccination.
29 These samples were tested using two serologic assays: one detecting antibodies elicited by
30 infection, and not by vaccines, and one detecting antibodies elicited by both infection and
31 vaccination. We used Bayesian statistical models to estimate the proportion of the
32 population that was naturally infected and the proportion protected due to vaccination.

33
34 *Findings:* We estimated that the risk of prior infection of Latinx residents was 5.3 (95% CI:
35 3.2 - 10.3) times greater than the risk of white residents aged 18-64 and that white San
36 Francisco residents over the age of 65 were twice as likely (2.0, 95% CI: 1.1 - 4.6) to be
37 vaccinated as Black residents. We also found socioeconomically deprived zipcodes in the
38 city had high probabilities of natural infections and lower vaccination coverage than wealthier
39 zipcodes.

40
41 *Interpretation:* Using a platform we created for SARS-CoV-2 serologic data collection in San
42 Francisco, we characterized and quantified the stark disparities in infection rates and
43 vaccine coverage by demographic groups over the first year of the pandemic. While the
44 arrival of the SARS-CoV-2 vaccine has created a ‘light at the end of the tunnel’ for this
45 pandemic, ongoing challenges in achieving and maintaining equity must also be considered.

46
47 *Funding:* NIH, NIGMS, Schmidt Science Fellows in partnership with the Rhodes Trust and
48 the Chan Zuckerberg Biohub.

50

51 **Background**

52

53 During the initial waves of the COVID-19 pandemic, disparities in disease burden were
54 largely driven by differences in infection rates, as a result of factors including occupation,
55 ability to shelter in place or to take sick leave, access to testing, housing status and
56 crowding, and neighborhood exposure. In addition to driving disparities in infection rates with
57 this novel virus, existing structural inequalities are associated with disparities in the risk of
58 comorbidities such as diabetes and heart disease (as a result of factors such as, but not
59 limited to, nutrition, access to exercise and increased stress), which increase the likelihood
60 of hospitalization and death from COVID-19, and with disparities in access to healthcare
61 both in managing comorbidities and in accessing care for COVID-19.

62

63 As vaccine roll-outs advance in the United States and globally, there are disparities in both
64 vaccine access and uptake. These disparities are multifactorial and complex, including
65 reduced technology access and literacy¹, barriers in access to healthcare, concern about the
66 safety of the vaccines², mistrust as a result of a history of medical racism and discrimination,
67 and poor access to reliable information about the vaccine. In the age of vaccination,
68 policymakers must understand the way in which societal structures affect disparities in both
69 infection and vaccination. These disparities may interact to affect both population level
70 immunity and the burden of COVID-19 in different communities. This is relevant both in the
71 present and in the future, as policymakers consider the continued roll-out of vaccines in the
72 context of new variants, as well as preparing for and responding to other diseases.

73

74

75 Given the high levels of disease under-ascertainment, serology (i.e., the measurement of
76 antibodies) has been particularly useful for understanding SARS-CoV-2 infection levels in
77 the population. When there is variability in testing rates and healthcare seeking behavior,
78 serology is an even more useful tool. Serology provides a unique opportunity to measure
79 biomarkers of infection and vaccination simultaneously, and to relate these metrics to
80 demographic and geographic factors. In settings where vaccines based on the SARS-CoV-2
81 spike protein (e.g., currently available mRNA or adenovirus vector vaccines) are used,
82 measuring long-lived antibody responses to both spike and non-spike proteins can be used
83 to disentangle immune responses elicited by infection from vaccination. While structural
84 inequalities are by no means limited to the United States, here we focus on a case example
85 leveraging serology to understand inequalities from a domestic perspective.

86

87

88 Even in San Francisco, a city which has had a relatively successful early and sustained
89 COVID-19 response, and has achieved high vaccination coverage over the past few months,
90 reported case counts of COVID-19 and hospitalization rates have been higher in
91 socioeconomically deprived areas, amongst homeless individuals, and within the city's
92 Latinx and Black communities^{3,4}. Disparities in vaccination coverage have also been
93 reported, particularly in the early months of vaccine roll-out, creating a double burden for
94 some vulnerable communities. In San Francisco, whilst some disparities have now been
95 addressed, vaccination remains much lower in homeless individuals and in Black/African
96 American individuals⁵.

97

98 To measure disparities in both infection rates and vaccination, we leveraged a SARS-CoV-2
99 serosurveillance platform launched in March 2020 that utilizes residual blood samples taken
100 from two hospital networks in San Francisco. Estimates derived from this platform during the
101 first wave of the pandemic showed seroprevalence in Latinx individuals to be nearly two
102 times higher than in white individuals, and nearly two times higher in homeless individuals
103 than the population average⁶. We collected samples from 1,014 individuals undergoing

104 routine blood draws between February 4 and February 17, 2021, capturing transmission
105 during the first 11 months of the epidemic and the early roll-out of vaccination for those over
106 65 years old. These samples were tested using two serologic assays: one detecting
107 antibodies to SARS-CoV-2 elicited by infection and not by vaccines currently used in the US,
108 and one detecting antibodies to SARS-CoV-2 elicited by both infection and vaccination. We
109 used Bayesian statistical models to estimate the proportion of the population that was
110 seropositive due to natural infection and the proportion seropositive due to vaccination,
111 stratified by age, race and ZIP code of residence.

112 **Methods**

113 Data

114
115
116
117 As part of an existing serological survey⁶, residual serum samples from routine blood draws
118 from the University of California, San Francisco (UCSF) and San Francisco Department of
119 Public Health (SFDPH) inpatient and outpatient healthcare systems were sampled between
120 February 4 and February 17, 2021. A total of 1,091 samples were collected, of which 77
121 were excluded due to participation in a separate COVID research study, and a further 15
122 were later excluded from further analyses as they could not be linked to antibody test results.
123 The characteristics of the samples are illustrated in Table 1. The full inclusion and exclusion
124 criteria and sampling algorithm are described previously⁶.

125 Laboratory analysis

126
127
128 Each sample (N = 1014) was tested on two commercial SARS-CoV-2 serologic platforms.
129 The Ortho Clinical Diagnostics VITROS Anti-SARS-CoV-2 Total assay measures the total Ig
130 antibody response to the S1 subunit of the SARS-CoV-2 spike (S) protein and therefore is
131 expected to yield a positive results after natural infection or vaccination⁷. The Roche Elecsys
132 Anti-SARS-CoV-2 assay measures the total Ig antibody response to the SARS-CoV-2
133 nucleocapsid (N) protein⁸ and therefore is expected to yield a positive results after natural
134 infection but not after vaccination with vaccines based on the spike protein. In a previous
135 analysis assessing the test performance characteristics of many SARS-CoV-2 serological
136 assays, we found both assays to exhibit high sensitivity over time following infection⁹.

137 Univariate data analysis (by assay)

138
139
140 Seropositivity on the Vitros assay indicates whether or not an individual has had any prior
141 immune response to SARS-CoV-2, either through natural infection and/or vaccination. The
142 SARS-CoV-2 mRNA and adenovirus vector vaccines elicit immune responses to only the S
143 protein of the virus. Therefore, in contexts where these vaccines are used exclusively (such
144 as the United States), seropositivity on the Roche assay indicates whether an individual has
145 had a prior immune response to SARS-CoV-2 via infection. Assuming perfect test
146 performance characteristics, the difference between the proportion seropositive on Vitros
147 and the proportion seropositive on Roche indicates the proportion of the population that has
148 been vaccinated and has not been infected.

149
150 We used Binomial models in a Bayesian framework to first estimate seropositivity separately
151 by assay. We adjusted for the manufacturer-reported specificity of each assay (100% for
152 Vitros and 99.80% for Roche) and for in-house estimates of the sensitivity of each assay at 2
153 months post symptom onset among non-hospitalized individuals based on a longitudinal
154 post-infection study⁹, corresponding to 83.8% for Vitros and 90.0% for Roche. We note that
155 sensitivity was particularly consistent over time following infection for these assays, so our
156 results are robust to the choice of exact time point used. We computed 95% credible
157 intervals (Crl) to quantify uncertainty in posterior estimates. For these univariate analyses,

158 age was stratified into 4 groups (0-17 y, 18-34 y, 35-64 y, and 65+ y) and race/ethnicity was
159 stratified into 5 groups (Asian, Black, Latinx, White, and Other).

160

161 Bivariate data analysis (infection vs. vaccination)

162

163 We then conducted bivariate analyses using the results of each sample on both assays. We
164 used the data set of individuals who had a test result on both the Vitros and Roche assays,
165 and removed the 81 samples that had a result on only one assay. In addition, we removed
166 the 3 samples that tested negative on Vitros and positive on Roche, which likely reflects a
167 false negative result on the Vitros assay and/or a false positive result on the Roche assay
168 (Supplementary Table 1).

169

170 *For demographic analyses:* Age was stratified into 2 groups (18-64 y and 65+ y), and
171 race/ethnicity was stratified into 4 groups (Asian, Black, Latinx, and White). We omitted
172 individuals aged 0-17 y from this portion of the analysis, as individuals in that age group
173 were not eligible for vaccination during this time frame in San Francisco (February 2021).
174 The decision to choose 65 y as a cutoff was due to the age-based roll-out of SARS-CoV-2
175 vaccination and the expected resultant differences in vaccine coverage by age. We also
176 omitted individuals with race/ethnicity of "Other" due to lack of data on vaccine doses in this
177 demographic group that are used as a prior for estimation (see below). For each
178 combination of age group and race/ethnicity j , we estimated the marginal probabilities of
179 natural infection, $\text{Pr}(\text{inf})$, and of vaccination, $\text{Pr}(\text{vacc})$, separately as follows.

180

$$181 \quad n_{\text{Vitros +ve \& Roche +ve}, j} \sim \text{Binomial}(N_j, \text{Pr}(\text{inf}))$$

$$182 \quad n_{\text{Vitros +ve \& Roche -ve}, j} \sim \text{Binomial}(N_j, \text{Pr}(\text{vacc}|\text{uninf}) * [1 - \text{Pr}(\text{inf})])$$

$$183 \quad n_{\text{Vitros -ve \& Roche -ve}, j} \sim \text{Binomial}(N_j, [1 - \text{Pr}(\text{vacc}|\text{uninf})] * [1 - \text{Pr}(\text{inf})])$$

184

$$185 \quad \text{Pr}(\text{vacc}) \sim \text{Beta}(\mu_j, \kappa_j)$$

$$186 \quad \text{Pr}(\text{vacc}) = \text{Pr}(\text{vacc}|\text{inf}) * \text{Pr}(\text{inf}) + \text{Pr}(\text{vacc}|\text{uninf}) * [1 - \text{Pr}(\text{inf})]$$

187

188

189

190

191

192

193

194

[INSERT FIGURE 1 HERE]

195

196

197

198

199

200

201 N_j represents the number of individuals in our data set in group j who were included, and $n_{x,j}$
202 represents the number of individuals in group j with antibody results x . For this analysis, we
203 assumed perfect test performance characteristics. As $\text{Pr}(\text{vacc}|\text{inf})$ is not identified by our
204 data, and we do not assume that $\text{Pr}(\text{vacc}|\text{inf}) = \text{Pr}(\text{vacc}|\text{uninf})$, we set up a process to
205 estimate the hyper-priors μ_j (mean) and κ_j (precision) for each group j based on reported
206 vaccination coverage data. To do this, we first obtained the total population size M_j of group j
207 in San Francisco as well as the reported number of individuals in that group m_j who had
208 been vaccinated up to January 20, 2021 (i.e., 3 weeks before the weighted mean date of
209 sample collection, allowing for time to sero-conversion after vaccination). We then used a
210 hypergeometric distribution to sample N_j individuals without replacement from a population in
211 which m_j individuals had been vaccinated and $M_j - m_j$ had not. We then calculated the
212 empirical proportion of vaccinated individuals among the N_j in that simulation, and repeated

213 this procedure 10,000 times to obtain a prior distribution of $\text{Pr}(\text{vacc})$. This distribution was
214 used to estimate the hyper-priors of the Beta distribution. This procedure was performed
215 separately for each group j .

216
217 For geographic analyses, ZIP codes with fewer than 10 individuals were excluded. As data
218 on vaccine doses distributed by ZIP code during this time-frame was not available, we
219 modified the model above by assuming that vaccination was independent of infection, and
220 estimated a single $\text{Pr}(\text{inf})$ and $\text{Pr}(\text{vacc})$ for each ZIP code. To measure disparities in both
221 infection rates and vaccination, we leveraged a SARS-CoV-2 serosurveillance platform
222 launched in March 2020 that utilizes residual blood samples taken from two hospital
223 networks in San Francisco. Estimates derived from this platform during the first wave of the
224 pandemic showed seroprevalence in Latinx individuals to be nearly two times higher than in
225 white individuals, and nearly two times higher in homeless individuals than the population
226 average⁶. We collected samples from 1,014 individuals undergoing routine blood draws
227 between February 4 and February 17, 2021, capturing transmission during the first 11
228 months of the epidemic and the early roll-out of vaccination. These samples were tested
229 using two serologic assays: one detecting antibodies to SARS-CoV-2 elicited by infection
230 and not by vaccines currently used in the US, and one detecting antibodies to SARS-CoV-2
231 elicited by both infection and vaccination. We used Bayesian statistical models to estimate
232 the proportion of the population that was seropositive due to natural infection and the
233 proportion seropositive due to vaccination, stratified by age, race and ZIP code of residence.

234 Role of funding source

235 The authors confirm that the funding sources for this research had no role in the study
236 design, collection, analysis, interpretation of data, writing of the article or decision to submit
237 for publication.
238

239 **Results**

240
241
242 Between February 4, 2021, and February 17, 2021, we collected samples, from 1014
243 individual patients, from UCSF Health ($n = 698$ patients) and the San Francisco
244 Department of Public Health ($n = 316$ patients) networks. By design, the geographic
245 distribution of residents matched the proportion of the San Francisco population living in
246 each zip code (**Fig. 2**). Our sample was equally distributed by sex, however over-
247 represented the 65+ age range and underrepresented the 0-34 age range relative to the San
248 Francisco population (**Table 1**). Our results were relatively representative of the San
249 Francisco population by race and ethnicity, although our sample overrepresented those who
250 identified as Black/African American and slightly underrepresented those who identified as
251 Asian.

252
253 Following testing samples on both Vitros and Roche assays, of the sampled population
254 where assay results were complete ($N = 915$), we found that while 28.4% ($N = 260$) tested
255 positive on the Vitros assay and therefore antibodies to SARS-CoV-2 were detected, only
256 8.6% ($N = 79$) tested positive on the Roche assay, detecting antibodies elicited by prior
257 natural infection (Figure 1). Of the 999 samples where assay results were returned, $N = 81$
258 samples were excluded from the analyses due to missing data in at least one assay, and 3
259 additional samples were excluded due to positive results on the Roche assay despite
260 negative results on the Vitros assay.

261
262

263
264
265
266

[INSERT FIGURE 2 HERE]

267 **Table 1: Sample Characteristics.** Table showing the sample size and distribution of the
 268 sample population by demography and hospital system, compared to the San Francisco
 269 Population as determined by the American Community Survey 2019.

	N	%	SF Population (ACS 2019)
Age			
0-17	21	2.10%	13.40%
18-34	157	15.50%	30.60%
35-64	442	43.60%	40.60%
65+	393	38.80%	15.40%
Unknown	1	0.10%	N/A
Sex			
Female	509	50.20%	49.30%
Male	504	49.70%	50.70%
Unknown	1	0.10%	N/A
Hospital			
UCSF	698	68.80%	N/A
ZSFG	316	31.20%	N/A
Race/Ethnicity			
Asian	282	27.80%	34.60%
Black or African American	115	11.30%	5.20%
Hispanic or Latino	175	17.30%	15.20%
Other	75	7.40%	5.20%
White	367	36.20%	39.80%

270
 271
 272
 273
 274
 275
 276
 277
 278

279 Our estimated probabilities of vaccination and prior infection stratified by age, race/ethnicity
280 and ZIP code showed striking differences in prior infection rates and vaccination rates
281 across the city (**Figure 3, Supplementary Table 2**). Across all age and demographic
282 groups, ZIP codes in the southeastern region of the city, comprising medically underserved
283 neighborhoods, had demonstrably higher rates of prior infection and lower rates of
284 vaccination. This pattern is not evident in estimated seroprevalence by the vitros assay
285 which captures antibody responses acquired through natural infection and/or vaccination.
286 For example, within the 94124 zipcode, Bayview-Hunter's Point, one of the city's most
287 deprived zipcodes, the mean probability of prior infection was 0.155 (95% CI: 0.077 - 0.254)
288 and vaccination was 0.079 (0.019-0.163), whereas 94115, Pacific Heights, one of the
289 wealthier zipcodes in San Francisco with a median household income almost double that of
290 Bayview-Hunter's Point at 123,037¹⁰, the probability of infection was just 0.023 (0.001,
291 0.080) and vaccination was 0.359 (0.258 - 0.467).

292
293 We found the highest seroprevalence as a result of prior infection in younger age groups
294 (using the Roche assay, **Figure 4a, Supplementary Table 3**). We estimated
295 seroprevalence derived from both vaccination and natural infection using the Vitros assay
296 showed much higher seroprevalence in those aged over 65 (**Figure 4b, Supplementary**
297 **Table 3**), consistent with the eligibility criteria for vaccination in the weeks before the
298 sampling period.

299
300 We identified differences in prior infection rates by race/ethnicity (**Figure 4c-d**): we
301 estimated that the risk of prior infection of Latinx residents was 5.3 (95% CI: 3.2 - 10.3) times
302 greater than the risk of white residents aged 18-64 (**Figure 5a, Supplementary Table 3**).
303 These trends were echoed in older individuals (aged 65+) (**Figure 5a, Supplementary**
304 **Table 3**). We also identified disparities in vaccination coverage among the 65+ year old
305 population, who were eligible to receive the vaccine during this time period. We estimated
306 that White San Francisco residents over the age of 65 were twice as likely (2.0, 95% CI: 1.1
307 - 4.6) to be vaccinated as Black residents.

308
309 Taken together, these findings imply that there is an imbalance between the risk of infection
310 and the rate of vaccination in certain populations. Among the 65+ year old population, we
311 found greatly increased ratios of vaccination compared to infection risk among Asian and
312 white individuals, while this was much lower among Black and Latinx individuals (**Figure 5b,**
313 **Supplementary Table 4**). For every naturally infected Asian resident of this age group,
314 there were 12.2 vaccinated Asian residents (95%CI: 4.2 - 55.5), whereas for every naturally
315 infected Latinx resident of this age group, there were only 1.6 vaccinated Latinx residents
316 (95% CI: 0.7 – 3.7). For both Latinx and Black individuals over 65 years old, the risk of
317 having immunity acquired through vaccination, relative to natural infection, was up to four
318 times lower than for white individuals.

319
320
321
322
323
324
325
326

[INSERT FIGURES 3-5 HERE]

327 Discussion

328 Using serological data, we quantified disparities in both vaccination coverage and infection
329 rates across different demographic groups and geographies and show that, during early
330 vaccine roll-out, vaccination coverage was much higher in Asian and White populations,
331 despite experiencing lower risk of infection by SARS-CoV-2 than Black and Hispanic/Latinx
332 populations.

333 The “double burden” we observed in San Francisco during the early vaccine roll-out echoes
334 broader patterns that have been observed in San Francisco and elsewhere. Even though
335 San Francisco was hailed as the first major US city to reach the milestone of 80%
336 vaccination coverage in adults¹¹, recent increases in infection have been found to be
337 concentrated in the neighborhoods which were hardest hit by initial infections and where we
338 found vaccination-related immunity was lowest¹². A report from the University of Texas found
339 striking geographic and racial stratification of cases of COVID-19 and vaccination rates in
340 Austin, Texas, which also closely mapped with indices of deprivation and social vulnerability
341 over ZIP codes¹³. Like in San Francisco, the neighborhoods which were predominantly
342 Latinx communities and had higher indices of deprivation also had higher incidence of
343 SARS-CoV-2 infection and lower vaccination coverage. Disparities in SARS-CoV-2
344 vaccination coverage among socially vulnerable populations have been documented across
345 the United States¹⁴ and in other parts of the world¹⁵.

346 There are several caveats and limitations to the approach introduced here. The Roche assay
347 can only differentiate antibody responses resulting from natural infections in settings where
348 Spike- based vaccines are used (that do not generate antibody responses against the
349 nucleocapsid), so in geographies where other vaccines are used this approach won't be
350 suitable. Although we used samples obtained through DPH health network, meaning we
351 included un-insured and under-insured individuals, we still are only able to capture those
352 seeking healthcare or reached by the SF DPH.

353
354 While inequalities revealed during COVID-19 are not new, the pandemic has highlighted the
355 ways in which even a city such as San Francisco which invests deeply in public health and
356 social safety nets still has deep structural inequalities, through a combination of higher
357 infection rates, incompatibility of living or work conditions with risk reduction, and lower or
358 delayed access to vaccines as they were rolled out.

359
360 Various initiatives are underway around the country to pinpoint geographic and other
361 disparities in the context of COVID-19 (e.g.,^{16,17}). However, as well as highlighting
362 disparities, it is important to consider what successful testing and vaccination initiatives may
363 look like and which may be learnt from in future measures. For example, within San
364 Francisco, robust community-academic partnerships have been key for effectively
365 responding to the pandemic in vulnerable communities¹⁸ and for narrowing gaps in
366 vaccination coverage, such as low-barrier neighborhood vaccination sites¹⁹. Prospectively,
367 as we gain a better understanding of waning immunity and the potential need for vaccine
368 booster doses, considerations of equity will remain an important consideration for allocating
369 resources. In the context of the United States, where vaccination and infection elicit different
370 immune responses, serology provides a powerful lens through which we can quantify these
371 disparities directly. In addition, it is important to consider the desired metric before
372 conducting a serosurvey, as assays measure different pathways to immunity and any
373 disparities in infection rates may be masked by using assays that measure overall antibody
374 prevalence.

375
376
377 Since the early days of the pandemic, many policy recommendations have been made for
378 ways to reduce health disparities in infection²⁰ and vaccination²¹. Policymakers must invest

379 in addressing both the upstream, structural drivers of health disparities, such as providing
380 workers with a living wage, affordable housing, and access to quality healthcare and also
381 downstream drivers such as improved community engagement, targeted testing and
382 vaccination provision, and assistance with common barriers to accessing healthcare such as
383 technology access/literacy, transport, and providing accessible health information in multiple
384 languages. While the arrival of the SARS-CoV-2 vaccine has created a 'light at the end of
385 the tunnel' for this pandemic, ongoing challenges that long predate COVID-19 in achieving
386 and maintaining equity must also be considered.

387
388
389

References

- 390 1 Press, Valerie G. , Megan Huisinigh-Scheetz, and Vineet M. Arora. Inequities in
391 Technology Contribute to Disparities in COVID-19 Vaccine Distribution. *JAMA Health*
392 *Forum* 2021; **2**: e210264.
- 393 2 Callaghan T, Moghtaderi A, Lueck JA, *et al.* Correlates and disparities of intention to
394 vaccinate against COVID-19. *Soc Sci Med* 2021; **272**: 113638.
- 395 3 Chamie G, Marquez C, Crawford E, *et al.* SARS-CoV-2 Community Transmission
396 disproportionately affects Latinx population during Shelter-in-Place in San Francisco.
397 *Clin Infect Dis* 2020; published online Aug 21. DOI:10.1093/cid/ciaa1234.
- 398 4 Imbert E, Kinley PM, Scarborough A, *et al.* Coronavirus Disease 2019 Outbreak in a
399 San Francisco Homeless Shelter. *Clinical Infectious Diseases*. 2021; **73**: 324–7.
- 400 5 COVID-19 Vaccine Doses Given to San Franciscans by Demographics. 2021; published
401 online March 6. [https://data.sfgov.org/COVID-19/COVID-19-Vaccine-Doses-Given-to-](https://data.sfgov.org/COVID-19/COVID-19-Vaccine-Doses-Given-to-San-Franciscans-by/wv2h-rqwk)
402 [San-Franciscans-by/wv2h-rqwk](https://data.sfgov.org/COVID-19/COVID-19-Vaccine-Doses-Given-to-San-Franciscans-by/wv2h-rqwk) (accessed Sept 20, 2021).
- 403 6 Routledge I, Epstein A, Takahashi S, *et al.* Citywide serosurveillance of the initial SARS-
404 CoV-2 outbreak in San Francisco using electronic health records. *Nat Commun* 2021;
405 **12**: 3566.
- 406 7 The Food and Drug Administration. VITROS Immunodiagnostic Products Anti-SARS-
407 CoV-2 IgG Reagent Pack - Instructions for Use. The Food and Drug Administration
408 <https://www.fda.gov/media/137363/download>.
- 409 8 The Food and Drug Administration. Elecsys Anti-SARS-CoV-2 - Instructions for Use.
410 The Food and Drug Administration, 2021 <https://www.fda.gov/media/137605/download>.
- 411 9 Peluso MJ, Takahashi S, Hakim J, *et al.* SARS-CoV-2 antibody magnitude and
412 detectability are driven by disease severity, timing, and assay. *medRxiv* 2021; published
413 online March 5. DOI:10.1101/2021.03.03.21251639.
- 414 10 U.S. Census Bureau. 2015-2019 American Community Survey 5-Year Estimates. 2020.
415 [https://data.census.gov/cedsci/table?q=income%20%20zipcode%20tabulation%20area](https://data.census.gov/cedsci/table?q=income%20%20zipcode%20tabulation%20area&g=8600000US94115,94124&tid=ACSST5Y2019.S1903&hidePreview=true)
416 [&g=8600000US94115,94124&tid=ACSST5Y2019.S1903&hidePreview=true](https://data.census.gov/cedsci/table?q=income%20%20zipcode%20tabulation%20area&g=8600000US94115,94124&tid=ACSST5Y2019.S1903&hidePreview=true) (accessed
417 Oct 15, 2021).
- 418 11 San Francisco Office of the Mayor. San Francisco Reaches Milestone: 80% of Eligible
419 Residents Have Received at Least One Vaccine Dose. [https://sfmayor.org/article/san-](https://sfmayor.org/article/san-francisco-reaches-milestone-80-eligible-residents-have-received-least-one-vaccine-dose)
420 [francisco-reaches-milestone-80-eligible-residents-have-received-least-one-vaccine-](https://sfmayor.org/article/san-francisco-reaches-milestone-80-eligible-residents-have-received-least-one-vaccine-dose)
421 [dose](https://sfmayor.org/article/san-francisco-reaches-milestone-80-eligible-residents-have-received-least-one-vaccine-dose) (accessed Aug 9, 2021).
- 422 12 Neilson S. Who is the coronavirus surge impacting in San Francisco? 2021; published

- 423 online July 19. [https://www.sfchronicle.com/health/article/Who-is-the-Covid-19-surge-](https://www.sfchronicle.com/health/article/Who-is-the-Covid-19-surge-impacting-in-San-16321854.php)
424 [impacting-in-San-16321854.php](https://www.sfchronicle.com/health/article/Who-is-the-Covid-19-surge-impacting-in-San-16321854.php) (accessed Aug 9, 2021).
- 425 13 Spencer Woody, Emily Javan, Kaitlyn Johnson, Remy Pasco, Maureen JohnsonLeón,
426 Michael Lachmann, Spencer J. Fox, Lauren Ancel Meyers. Spatial distribution of
427 COVID-19 infections and vaccinations in Austin, Texas. 2021 DOI:10.15781/m60y-tc90.
- 428 14 Hughes MM, Wang A, Grossman MK, *et al.* County-Level COVID-19 Vaccination
429 Coverage and Social Vulnerability - United States, December 14, 2020-March 1, 2021.
430 *MMWR Morb Mortal Wkly Rep* 2021; **70**: 431–6.
- 431 15 Paton J. U.K. Vaccination Rates Struggle in Places Worst-Hit by Covid-19. Bloomberg
432 News. 2021; published online March 30. <https://www.bloomberg.com> (accessed Aug 17,
433 2021).
- 434 16 Advance OC. Orange County Equity Map. 2020; published online Dec 30.
435 <https://www.advanceoc.com/orange-county-equity-map/> (accessed Aug 9, 2021).
- 436 17 Dottle R, Tartar A, Greenfield R, Qiu Y. Tracking Covid Vaccines by Race: Black and
437 Hispanic Rates Lower Than White and Asian. 2021; published online Feb 17.
438 [https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/us-](https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/us-vaccine-demographics.html)
439 [vaccine-demographics.html](https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/us-vaccine-demographics.html) (accessed Aug 17, 2021).
- 440 18 Fields Jessica, Gutierrez J Raul, Marquez Carina, *et al.* Community-Academic
441 Partnerships to Address Covid-19 Inequities: Lessons from the San Francisco Bay
442 Area. *Catalyst non-issue content*; **2**. DOI:10.1056/CAT.21.0135.
- 443 19 Marquez C, Kerkhoff AD, Naso J, *et al.* A multi-component, community-based strategy
444 to facilitate COVID-19 vaccine uptake among Latinx populations: from theory to
445 practice. *medRxiv* 2021; : 2021.06.07.21258230.
- 446 20 Wang ML, Behrman P, Dulin A, *et al.* Addressing inequities in COVID-19 morbidity and
447 mortality: research and policy recommendations. *Transl Behav Med* 2020; **10**: 516–9.
- 448 21 Fernández L, Shorett P. Lessons in Equity From the Front Lines of COVID-19
449 Vaccination. *JAMA Health Forum* 2021; **2**: e210612–e210612.
- 450 22 San Francisco Department of Public Health. COVID-19 Vaccine Doses Given to San
451 Franciscans by Demographics Over Time. 2021; published online March 11.
452 [https://data.sfgov.org/COVID-19/COVID-19-Vaccine-Doses-Given-to-San-Franciscans-](https://data.sfgov.org/COVID-19/COVID-19-Vaccine-Doses-Given-to-San-Franciscans-by/xjh5-h442)
453 [by/xjh5-h442](https://data.sfgov.org/COVID-19/COVID-19-Vaccine-Doses-Given-to-San-Franciscans-by/xjh5-h442) (accessed Aug 5, 2021).
- 454 23 Department of Public Health - Population Health Division. COVID-19 Cases
455 Summarized by Date, Transmission and Case Disposition. 2020; published online April
456 6. [https://data.sfgov.org/COVID-19/COVID-19-Cases-Summarized-by-Date-](https://data.sfgov.org/COVID-19/COVID-19-Cases-Summarized-by-Date-Transmission-and/tvq9-ec9w)
457 [Transmission-and/tvq9-ec9w](https://data.sfgov.org/COVID-19/COVID-19-Cases-Summarized-by-Date-Transmission-and/tvq9-ec9w) (accessed Aug 8, 2021).

458
459
460
461
462
463
464
465
466

467 **Figure Legends**

468

469 **Figure 1: Schematic of parameters to be estimated using serosurveillance platform**
470 **(shown in red, blue and gold).** Red represents the probability of vaccination given prior
471 infection, $\Pr(\text{vacc}|\text{inf})$, blue represents the probability of prior infection, $\Pr(\text{inf})$, and gold
472 represents the probability of vaccination given no prior history of infection, $\Pr(\text{vacc}|\text{uninf})$.

473

474 **Figure 2: Sample characteristics. (A)** Age distribution by hospital week of sample
475 collection within the University of California, San Francisco (UCSF) and San Francisco
476 Department of Public Health (ZSFG) hospital networks. Each point represents a sample and
477 colors correspond to age bins used for analysis. **(B)** Proportion of samples from a given San
478 Francisco zipcode plotted against the proportion of the San Francisco population within that
479 zipcode. Colors show the percentage of residents below the poverty line within that zipcode,
480 as determined by the American Community Survey 2019.

481

482

483 **Figure 3: Maps showing geographic disparities in SARS-CoV-2 within San Francisco.**

484 Maps show (a) estimated probability of prior infection and (b) probability of vaccination by
485 ZIP code in San Francisco, as of February 2021.

486

487 **Figure 4: Stratified seroprevalence by assay and by demographic group. (A)** Univariate
488 Roche seropositivity estimates by age (elicited by prior infection). **(B)** Univariate Vitros
489 estimates by age (elicited by either prior infection or vaccination). **(C)** Univariate Roche
490 estimates by race/ethnicity. **(D)** Univariate Vitros estimates by race/ethnicity.

491

492 **Figure 5: Relationship between probability of vaccination and probability of prior**
493 **infection by race/ethnicity. a)** Probability of infection vs. probability of vaccination by age
494 and race/ethnicity. **b)** Infographic showing the number of estimated people vaccinated for
495 every one person previously naturally infected in San Francisco within each
496 racial/demographic group.


497

498

499


500

501 **Figure 1: Schematic of parameters to be estimated using serosurveillance platform**
502 **(shown in red, blue and gold).** Red represents the probability of vaccination given prior
503 infection, $\Pr(\text{vacc}|\text{inf})$, blue represents the probability of prior infection, $\Pr(\text{inf})$, and gold
504 represents the probability of vaccination given no prior history of infection, $\Pr(\text{vacc}|\text{uninf})$.
505
506
507




508
509
510
511

512 **Figure 2: Sample characteristics. (A)** Age distribution by hospital week of sample
513 collection within the University of California, San Francisco (UCSF) and San Francisco
514 Department of Public Health (ZSFG) hospital networks. Each point represents a sample and
515 colors correspond to age bins used for analysis. **(B)** Proportion of samples from a given San
516 Francisco zipcode plotted against the proportion of the San Francisco population within that
517 zipcode. Colors show the percentage of residents below the poverty line within that zipcode,
518 as determined by the American Community Survey 2019.
519
520
521




522 **Figure 3: Maps showing geographic disparities in SARS-CoV-2 within San Francisco.**
523 Maps show (a) estimated probability of prior infection and (b) probability of vaccination by
524 ZIP code in San Francisco, as of February 2021.
525




526

527 **Figure 4: Stratified seroprevalence by assay and by demographic group. (A)** Univariate
528 Roche seropositivity estimates by age (elicited by prior infection). **(B)** Univariate Vitros
529 estimates by age (elicited by either prior infection or vaccination). **(C)** Univariate Roche
530 estimates by race/ethnicity. **(D)** Univariate Vitros estimates by race/ethnicity.
531



532 **Figure 5: Relationship between probability of vaccination and probability of prior**
533 **infection by race/ethnicity. a) Probability of infection vs. probability of vaccination by age**
534 **and race/ethnicity. b) Infographic showing the number of estimated people vaccinated for**
535 **every one person previously naturally infected in San Francisco within each**
536 **racial/demographic group.**
537




538
539
540
541
542
543
544
545
546
547
548

Supplementary Figures and Tables

Supplementary Figure 1: Geographic disparities in SARS-CoV-2 infection and vaccination by ZIP code in San Francisco, as of February 2021 (univariate). (A)


Adjusted seroprevalence on the Roche assay (reflecting natural infection only). (B) Adjusted seroprevalence on the Vitros assay (reflecting both natural infection and/or vaccination). (C) The difference in adjusted seroprevalence on the Vitros and Roche assays (reflecting those who were seropositive by vaccination only).



549
550


551
552
553

Supplementary Figure 2: Pathways to immunity via infection and vaccination.




554
555
556
557
558
559
560

Supplementary Figure 3: Cumulative proportion of individuals who received the first dose of SARS-CoV-2 vaccine by date, age group, and race/ethnicity. Sampling period of this study shown in grey box. Data downloaded from ²².



561
562

563 **Supplementary Figure 4: Time series of reported SARS-CoV-2 cases and deaths in**
564 **San Francisco.** Sampling period of this study shown in red box. Data downloaded from ²³.
565



566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600

601 **Supplementary Table 1 : Interpretation of bivariate antibody results on the Vitros and**
602 **Roche assays.**
603

Vitros result	Roche result	Interpretation for bivariate analyses (n)
Positive	Positive	Infected and (either vaccinated or unvaccinated) (n=79)
Positive	Negative	Uninfected and vaccinated (n=181)
Negative	Negative	Uninfected and unvaccinated (n=655)
Negative	Positive	False negative on Vitros and/or false positive on Roche (n=3; removed)
Positive	No result	(n=15; removed)
Negative	No result	(n=43; removed)
No result	Positive	(n=2; removed)
No result	Negative	(n=21; removed)

604
605

606
607
608

Supplementary Table 2: Bivariate posteriors by ZIP code.

zcta	Mean, P(vaccination)	Mean, P(infection)	2.5%, P(vaccination)	2.5%, P(infection)	50%, P(vaccination)	50%, P(infection)	97.5%, P(vaccination)	97.5%, P(infection)	n_samples
94102	0.166	0.124	0.073	0.048	0.164	0.121	0.273	0.224	36
94103	0.097	0.169	0.025	0.079	0.091	0.166	0.203	0.278	31
94105	0.060	0.166	0.002	0.044	0.046	0.158	0.193	0.333	13
94107	0.156	0.059	0.066	0.008	0.152	0.053	0.266	0.147	28
94108	0.180	0.057	0.056	0.001	0.171	0.044	0.349	0.186	12
94109	0.257	0.101	0.178	0.046	0.256	0.099	0.341	0.170	65
94110	0.198	0.178	0.123	0.108	0.198	0.176	0.279	0.256	75
94112	0.219	0.145	0.145	0.087	0.218	0.143	0.298	0.212	86
94114	0.198	0.070	0.105	0.017	0.195	0.065	0.307	0.153	38
94115	0.359	0.023	0.258	0.001	0.357	0.016	0.467	0.080	39
94116	0.135	0.056	0.066	0.014	0.132	0.051	0.219	0.120	48
94117	0.177	0.042	0.097	0.006	0.175	0.037	0.273	0.108	41
94118	0.217	0.041	0.131	0.005	0.215	0.036	0.313	0.107	43
94121	0.315	0.052	0.229	0.012	0.313	0.048	0.407	0.115	53
94122	0.292	0.058	0.210	0.017	0.291	0.055	0.382	0.118	65
94123	0.197	0.038	0.086	0.001	0.192	0.028	0.331	0.126	21
94124	0.075	0.155	0.019	0.077	0.070	0.153	0.163	0.254	40
94127	0.322	0.097	0.166	0.015	0.317	0.088	0.494	0.235	17
94131	0.357	0.031	0.232	0.001	0.355	0.022	0.491	0.111	28
94132	0.299	0.162	0.185	0.073	0.298	0.159	0.421	0.266	40
94133	0.215	0.067	0.106	0.011	0.211	0.060	0.348	0.161	25
94134	0.257	0.231	0.136	0.130	0.255	0.227	0.392	0.347	36

609
610
611
612

613 **Supplementary Table 3: Univariate posteriors by demography.**

614

Assay	Demographic Group	Median	CI.2.5%	CI.97.5%
Roche	0-17	0.451	0.240	0.681
Vitros	0-17	0.518	0.291	0.767
Roche	18-34	0.173	0.116	0.243
Vitros	18-34	0.277	0.202	0.364
Roche	35-64	0.101	0.074	0.136
Vitros	35-64	0.223	0.180	0.271
Roche	65+	0.043	0.024	0.070
Vitros	65+	0.479	0.420	0.539
Roche	Asian	0.035	0.015	0.065
Vitros	Asian	0.331	0.269	0.399
Roche	Black or African American	0.086	0.038	0.157
Vitros	Black or African American	0.201	0.127	0.289
Roche	Hispanic or Latino	0.321	0.250	0.399
Vitros	Hispanic or Latino	0.463	0.380	0.551
Roche	Other	0.102	0.042	0.186
Vitros	Other	0.313	0.204	0.444
Roche	White	0.046	0.026	0.072
Vitros	White	0.328	0.270	0.387

615

616

617

618 **Supplementary Table 4: Bivariate antibody results by age and race/ethnicity.**
 619 Probability of vaccination given infected, probability of vaccination given uninfected,
 620 probability of infection, probability of vaccination, probability of vaccination divided by
 621 probability of infection (“risk ratio”), and relative risk ratio with a reference group of White
 622 race/ethnicity and the corresponding age.
 623

Age	Race/Ethnicity	parameter	median	lb_2.5	ub_97.5
18-64	Asian	p_vacc_given_inf	0.216	0.008	0.875
18-64	Black	p_vacc_given_inf	0.303	0.012	0.932
18-64	Latinx	p_vacc_given_inf	0.053	0.002	0.261
18-64	White	p_vacc_given_inf	0.125	0.005	0.620
65+	Asian	p_vacc_given_inf	0.233	0.007	0.891
65+	Black	p_vacc_given_inf	0.387	0.015	0.958
65+	Latinx	p_vacc_given_inf	0.270	0.010	0.914
65+	White	p_vacc_given_inf	0.105	0.003	0.688
18-64	Asian	p_vacc_given_uninf	0.099	0.065	0.137
18-64	Black	p_vacc_given_uninf	0.074	0.036	0.124
18-64	Latinx	p_vacc_given_uninf	0.086	0.045	0.141
18-64	White	p_vacc_given_uninf	0.078	0.052	0.108
65+	Asian	p_vacc_given_uninf	0.294	0.245	0.344
65+	Black	p_vacc_given_uninf	0.130	0.054	0.241
65+	Latinx	p_vacc_given_uninf	0.285	0.168	0.420
65+	White	p_vacc_given_uninf	0.316	0.269	0.364
18-64	Asian	p_inf	0.046	0.019	0.086
18-64	Black	p_inf	0.069	0.031	0.124
18-64	Latinx	p_inf	0.291	0.232	0.355
18-64	White	p_inf	0.054	0.028	0.088
65+	Asian	p_inf	0.024	0.005	0.067
65+	Black	p_inf	0.081	0.022	0.184
65+	Latinx	p_inf	0.188	0.090	0.311
65+	White	p_inf	0.046	0.016	0.096
18-64	Asian	p_vacc	0.106	0.072	0.147
18-64	Black	p_vacc	0.093	0.046	0.154
18-64	Latinx	p_vacc	0.080	0.042	0.145
18-64	White	p_vacc	0.083	0.056	0.116
65+	Asian	p_vacc	0.292	0.244	0.343
65+	Black	p_vacc	0.155	0.068	0.270
65+	Latinx	p_vacc	0.290	0.165	0.438
65+	White	p_vacc	0.308	0.260	0.358
18-64	Asian	ratio_p_vacc_p_inf	2.314	1.016	6.304
18-64	Black	ratio_p_vacc_p_inf	1.368	0.510	3.388
18-64	Latinx	ratio_p_vacc_p_inf	0.275	0.134	0.526
18-64	White	ratio_p_vacc_p_inf	1.515	0.754	3.350
65+	Asian	ratio_p_vacc_p_inf	12.220	4.188	55.534
65+	Black	ratio_p_vacc_p_inf	1.912	0.559	7.817
65+	Latinx	ratio_p_vacc_p_inf	1.572	0.655	3.705
65+	White	ratio_p_vacc_p_inf	6.676	2.930	20.444
18-64	Asian	RRR_vs_white_of_that_age	1.571	0.493	4.832
18-64	Black	RRR_vs_white_of_that_age	0.875	0.265	2.883

		e			
18-64	Latinx	RRR_vs_white_of_that_age	0.184	0.064	0.495
18-64	White	RRR_vs_white_of_that_age	1.000	1.000	1.000
65+	Asian	RRR_vs_white_of_that_age	1.831	0.405	9.568
65+	Black	RRR_vs_white_of_that_age	0.291	0.060	1.489
65+	Latinx	RRR_vs_white_of_that_age	0.231	0.058	0.788
65+	White	RRR_vs_white_of_that_age	1.000	1.000	1.000

624
625

626 **Data sharing statement**

627

628 All analysis was conducted using the R statistical software and the Stan programming
629 language. All code to reproduce these results are available at:

630 <https://github.com/EPPICenter/scale-it-2>.

631

632

633 **Declaration of Interests**

634 The authors have no conflicts of interest to declare.

635

636 **Acknowledgements**

637 We acknowledge sources of funding support, including from the Schmidt Science Fellows, in
638 partnership with the Rhodes Trust (ST); Chan Zuckerberg Biohub Investigator program (BG);
639 the ZSFG Department of Medicine and Division of HIV, ID, and Global Medicine; the MIDAS
640 Coordination Center COVID-19 Urgent Grant Program (MIDASNI2020-5) by a grant from the
641 National Institute of General Medical Science (3U24GM132013-02S2) (IR, ST, IRB); and the
642 National Institutes of Health/National Institute of General Medical Sciences R35GM138361-
643 02 (IRB). We acknowledge Dr. Carina Marquez for helpful comments on the manuscript. We
644 acknowledge Valerie Green and Phillip Williamson at Creative Testing Solutions for
645 performing the Roche testing. We acknowledge the groups of Dr. Kara Lynch and Dr. Alan
646 Wu for facilitating the collection of samples at ZSFG. We acknowledge the groups of Dr. Lee
647 Besana and Dr. Marcelina Coh for facilitating the collection of samples at UCSF.

648

649

650 **Research in context**

651

652 **Evidence before this study**

653 We searched PubMed on October 13, 2021, using the following search terms: (inequalit* OR
654 disparit*) AND (vaccination OR vaccine) AND (infect* OR exposure) AND (COVID* OR
655 SARS-CoV-2 OR SARS-CoV), published in 2021 (i.e. after the roll-out of vaccination) with
656 no language restrictions. We identified 145 publications, including original research,
657 commentaries, systematic reviews and meta-analyses and reviews. Although many studies
658 discussed or quantified disparities in either vaccination or infection risk, we did not find any
659 studies which measured the combined effect or interaction between disparities in vaccination
660 and infection risk, or quantified the effect of these disparities on population-level immunity.

661

662 **Added value of this study**

663 To our knowledge, this is the first study to jointly measure disparities in vaccination and
664 infection using serological data. Serosurveillance systems leveraging demographically-
665 stratified residual serum samples, like the one we implemented, are affordable and flexible,
666 and could be used by Public Health systems to monitor health disparities as they avoid some
667 of the biases inherent in metrics such as case counts and test positivity rates. We also show
668 how vaccination coverage may be monitored, which can be challenging when integrating
669 data from multiple healthcare systems and when denominator populations may be
670 inaccurate for calculating vaccination coverage.

671

672

673